Global Intellectual Property Specialists

Strategic global thinking for the pharmaceutical and biopharmaceutical industries

Our Capabilities

We use our global experience to support life sciences clients from early R&D to commercial launch, and beyond.

Explore our BioBlast®

View our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date.

Our People

Our lawyers and attorneys have science backgrounds, were trained at top tier firms, and most have experience in-house at multinational giants.

Award-winning IP services

Ranked internationally and domestically, our pharmaceutical, biopharmaceutical and life sciences focussed lawyers and attorneys are recognised as being among the best IP practitioners in the world.

Our Capabilities

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.

We coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.

Patent: Legal and Attorney Services

Trade Mark: Legal and Attorney Services

Commercial IP Services

Regulatory Affairs Services

View our Capabilities

Since its establishment in 2017 boutique Pearce IP has dominated in the area of pharmaceutical patents. Thanks to its deep bench of talented professionals, any life sciences brief is dispatched with alacrity and poise.

IAM Patent 1000, 2024

IP SPECIALISTS LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS

Our Leaders

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Adele Chadwick

Executive, Deputy CEO & Head of Talent

Paul Johns

Executive, Lawyer (Head of Litigation - New Zealand)

Chris Vindurampulle PhD

Executive, Patent & Trade Mark Attorney (Head of Patent Prosecution)

Kimberley Evans

Executive, Lawyer & Trade Mark Attorney (Head of Trade Marks)

Chris Coates (Maj Ret)

Executive, Finance

Helen Macpherson

Executive, Lawyer (Head of Litigation - Australia)

PEARCE IP BLOG

Read our latest updates & insights

Med Tech Giant Handed Largest Penalty Ever Given Under the Therapeutic Goods Act

by Naomi Pearce, Helen Macpherson, Imogen Bain | Dec 20, 2024

On 19 September 2024, the Federal Court of Australia delivered judgment ordering Medtronic Australasia Pty Ltd (Medtronic) to pay $22 million in penalties following proceedings bought by the Department of Health in August 2021…

Salt in the Wound: Federal Court Dissolves Novartis’ Patent Claims and Takes Aim at Hypothetical Tasks

by Naomi Pearce, Helen Macpherson, Nathan Kan | Dec 17, 2024

On 13 November 2024, Justice Yates of the Federal Court of Australia delivered his decision in the dispute between Novartis AG and Novartis Pharmaceuticals Australia Pty Limited (together, Novartis) and Pharmacor Pty Limited (Pharmacor) regarding patent AU2003206738 entitled “Pharmaceutical compositions comprising valsartan and NEP inhibitors” (the Patent).

Pearce IP BioBlast® for the week ending 13 December 2024

by Naomi Pearce, Chantal Savage, Nathan Kan | Dec 16, 2024

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 December 2024 are set out below: